Charles River Laboratories (CRL) Misses Q3 EPS by 1c; Tightens FY11 EPS Outlook
Charles River Laboratories Int'l (NYSE: CRL) reported Q3 EPS of $0.57, $0.01 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $277.6 million versus the consensus estimate of $280.45 million.
Charles River Laboratories sees FY2011 EPS of $2.40-$2.45, versus prior guidance of $2.38-$2.48 and the consensus of $2.45.
Charles River Laboratories sees FY2011 EPS of $2.40-$2.45, versus prior guidance of $2.38-$2.48 and the consensus of $2.45.